Tofacitinib for Steroid-Resistant Thyroid Eye Disease
Treatments studied
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests whether tofacitinib, a new type of immune-modulating medication, can help people with moderate-to-severe thyroid eye disease (Graves' orbitopathy) whose eyes haven't improved with standard steroid treatments. The goal is to reduce eye swelling, bulging, and inflammation that affects daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Diagnosed with Graves' orbitopathy (thyroid-related eye disease) with moderate-to-severe symptoms affecting daily activities
- Active disease with a Clinical Activity Score of 3 or higher, AND have either failed high-dose steroids (at least 3 grams of IV methylprednisolone) or cannot safely take steroids due to other health conditions
- Thyroid function is controlled or stable on medication for at least 4 weeks before entering the study
- Women of childbearing age must use effective birth control during and for 4 weeks after the study
- No sight-threatening complications, recent eye surgery, or use of certain other biologic drugs in the past 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called GenSci098 for people with active thyroid eye disease. It aims to reduce eye symptoms like redness, swelling, and bulging, and improve quality of life.
This trial tests a new drug called MHB018A for chronic thyroid eye disease (TED)—a condition where the eyes become inflamed and swollen due to thyroid problems. The study aims to see if this treatment can reduce eye inflammation and improve symptoms in people who have had TED for over a year.
This study tests an experimental pill (linsitinib) for people with active thyroid eye disease. Participation may help reduce eye bulging and other symptoms, especially if other treatments haven't worked.
This study tests whether a new medicine called MHB018A can reduce swelling and inflammation in thyroid eye disease (TED)—a condition where the immune system attacks tissues around the eyes, causing them to swell, bulge, and become uncomfortable. Researchers will compare MHB018A to placebo (a fake medicine) to see if it helps improve symptoms and appearance.
This study tests whether the cholesterol-lowering drug atorvastatin can help people with active, moderate-to-severe thyroid eye disease (swelling and bulging of the eyes caused by an overactive thyroid). You will receive the drug or a placebo alongside your usual steroid treatment, and your eyes will be checked over about a year.
This trial tests a new drug called ZL-1109 for people with active, moderate to severe thyroid eye disease (TED). It aims to see if the drug can reduce symptoms like bulging eyes and help patients feel better without using steroids.
Hear when a new Thyroid Eye Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.